Booth 5673

Gencor and its delivery systems technology partner Pharmako Biotechnologies will launch BioBerb, a cold water-dispersible berberine, at SupplySide Global.

The company will also unveil new science on its branded Oleoylethanolamide (OEA) ingredient, Trpti, validating its role in weight management, and a recent study on its PEA ingredient Levagen + demonstrating stress support in female college students.

Berberine is known for its antioxidant and inflammatory modulating activities, and its interaction with enzymes including AMPK, PKC, and SIRT1, which regulate energy, glucose metabolism, and immune function. Berberine also supports insulin activity, gut microbiome diversity, and may stimulate GLP-1.

Bioberb provides significantly improved absorption and bioavailability over traditional Barberry-based berberine extracts, which often require high doses to be effective and cause tolerability issues and adverse events. In a peer-reviewed clinical study, a single 188 mg dose of BioBerb delivered 801 ng/mL of total berberine into blood plasma.

“BioBerb is not just another supplement; it’s a smarter, more advanced way to support your health. If you’re serious about optimizing your energy, blood sugar, and overall metabolic function, BioBerb is a clear choice,” said George Kokkinis, CEO of Pharmako Biotechnologies.

“At Gencor, innovation begins with science that genuinely impacts how people feel and perform,” said John Quilter, CEO of Gencor. “With BioBerb, Trpti, and Levagen, we’re pushing the limits of what’s possible in natural metabolic and joint health support. These ingredients demonstrate our ongoing commitment to turning advanced clinical research into effective, accessible wellness solutions for today’s active consumers.”

Gencor will also be participating in an educational session, featuring Amanda Rao, PhD, from RDC Glboal, and Danielle Piomelli, PharmD, Phd, MD (h.c.), director of the University of California’s center for the study of cannabis and cannabinoid research and Rhizotomos Consulting. In this session, Rao will present new research on BioBerb, and Piomelli will discuss Trpti’s recent clinical study. The session will take place on Wednesday, Oct. 29 at the Product Development Theater, Booth 8076.